- In its most recent oral nicotine study, Lexaria established that DehydraTECH-oral nicotine delivery peaked in bloodstream 10x to 20x faster than controls and peak levels achieved were up to 10x higher than controls
- Lexaria hopes to evidence in its upcoming human oral nicotine study NIC-H22-1, that processing purified nicotine with DehydraTECH leads to better oral-tissue absorption and reduced negative experiences compared to currently sold brands
- Lexaria’s DehydraTECH technology works with new and existing drugs, processing them into a final form that increases bioavailability, speeds up onset and improves effectiveness that can allow for smaller doses
- The company also recently announced new agreements with tobacco giant Altria for evaluation of some of its powder-based nicotine formulations
Technology innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a drug delivery technology designed to increase bio-absorption, reduce time of onset and mask unwanted tastes of a wide variety of medicines and therapeutics.
In exploring the potential of its patented DehydraTECH(TM) technology, which uses a proprietary process to render active pharmaceutical ingredients into a readily absorbable final form, Lexaria has investigated DehydraTECH’s effectiveness in various markets such as hypertension, antivirals and oral nicotine to name a few, with outstanding results.
Another important area of study has focused on nicotine alternatives to replace smoking. This summer, the Company will begin a human clinical study, NIC-H22-1, which will dose a minimum of 36 people to compare Lexaria’s DehydraTECH-nicotine pouch performance with that of existing brands such as ON! and Zyn currently sold in the United States, drawing on existing capital to fund the study (https://cnw.fm/WtaDW). Animal testing has already demonstrated that DehydraTECH-nicotine can deliver peak nicotine performance to the bloodstream 10 to 20 times faster than the study’s controls (https://cnw.fm/mgn96).
In March, the company received its first ever patent granted to use DehydraTECH to deliver nicotine more efficiently through buccal tissue absorption in Australia (https://cnw.fm/ZSXqk). Buccal tissue is the type of tissue in your mouth and throat, allowing for the nicotine to be primarily absorbed before it enters the stomach. Similar patent filings have been made in the U.S. and in the EU and Lexaria believes those potential patent awards could support significant competitive advantages in the nicotine white pouch category, as well as other oral nicotine product formats.
The FDA has long resisted formal authorization of smokeless alternatives to tobacco consumption because of concerns about their capacity to lure youths into addiction.
“Anyone who does not currently use tobacco products, especially youth, should refrain from doing so,” Acting FDA Commissioner Ned Sharpless, M.D., said in relation to the agency’s authorization for some “Modified Risk Tobacco Products” to be marketed as a safer alternative to smoking in recent months. But in 2019, Swedish smokeless brand General became the first in the long history of the FDA to ever win that marketing allowance. (https://cnw.fm/eH7IZ).
Lexaria has long held that any form of inhaling chemical substances can be detrimental to health, and its DehydraTECH-nicotine aims to help vapers as well as smokers wean themselves off of those products, giving them relief from cravings while offering a safer nicotine alternative.
“My father also died from lung cancer … so I am no fan (of smoking),” CEO Chris Bunka told Forbes in 2019 (https://cnw.fm/yinGr). “The fact that (DehydraTECH) is fast means that smokers might not be frustrated waiting for their nicotine experience to begin, the way they have been with traditional nicotine products such as gums and lozenges.”
The company is working with the tobacco industry, and recently announced new agreements with tobacco giant Altria Client Services, LLC in which Lexaria will receive a fee to provide certain DehydraTECH powder-based nicotine formulations to Altria for evaluation (https://cnw.fm/y2LmV).
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CanadianCannabisWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.